TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-949-5200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees47
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Tcr2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions
What is Tcr2 Therapeutics' stock symbol?
Tcr2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."
How were Tcr2 Therapeutics' earnings last quarter?
Tcr2 Therapeutics Inc (NASDAQ:TCRR) posted its earnings results on Thursday, August, 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.57) by $0.11. View Tcr2 Therapeutics' Earnings History.
When is Tcr2 Therapeutics' next earnings date?
What price target have analysts set for TCRR?
6 equities research analysts have issued twelve-month price targets for Tcr2 Therapeutics' shares. Their predictions range from $16.00 to $37.00. On average, they anticipate Tcr2 Therapeutics' stock price to reach $27.80 in the next twelve months. This suggests a possible upside of 63.5% from the stock's current price. View Analyst Price Targets for Tcr2 Therapeutics.
What is the consensus analysts' recommendation for Tcr2 Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tcr2 Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tcr2 Therapeutics.
Has Tcr2 Therapeutics been receiving favorable news coverage?
News headlines about TCRR stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tcr2 Therapeutics earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Tcr2 Therapeutics.
Are investors shorting Tcr2 Therapeutics?
Tcr2 Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 738,100 shares, an increase of 17.8% from the July 31st total of 626,700 shares. Based on an average daily volume of 59,400 shares, the short-interest ratio is currently 12.4 days. Approximately 9.6% of the company's stock are sold short. View Tcr2 Therapeutics' Current Options Chain.
Who are some of Tcr2 Therapeutics' key competitors?
Some companies that are related to Tcr2 Therapeutics include Regenxbio (RGNX), Audentes Therapeutics (BOLD), Coherus Biosciences (CHRS), Momenta Pharmaceuticals (MNTA), Alector (ALEC), Orchard Therapeutics (ORTX), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), Twist Bioscience (TWST), BAVARIAN NORDIC/S (BVNRY), Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY) and NanoString Technologies (NSTG).
What other stocks do shareholders of Tcr2 Therapeutics own?
Who are Tcr2 Therapeutics' key executives?
Tcr2 Therapeutics' management team includes the folowing people:
- Dr. Garry E. Menzel, Pres, CEO & Director (Age 55)
- Mr. Robert Hofmeister, Chief Scientific Officer (Age 52)
- Dr. Alfonso Quintas Cardama M.D., Chief Medical Officer (Age 48)
- Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 46)
When did Tcr2 Therapeutics IPO?
(TCRR) raised $76 million in an initial public offering on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.
When did the company's lock-up period expire?
Tcr2 Therapeutics' lock-up period expired on Tuesday, August 13th. Tcr2 Therapeutics had issued 5,000,000 shares in its public offering on February 14th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Who are Tcr2 Therapeutics' major shareholders?
Tcr2 Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (0.80%), BlackRock Inc. (0.44%), Vanguard Group Inc. (0.31%), Parametric Portfolio Associates LLC (0.15%), Charles Schwab Investment Management Inc. (0.10%) and EcoR1 Capital LLC (0.07%). Company insiders that own Tcr2 Therapeutics stock include Morana Jovan-Embiricos and Upnorth Investment Ltd. View Institutional Ownership Trends for Tcr2 Therapeutics.
Which institutional investors are selling Tcr2 Therapeutics stock?
Which institutional investors are buying Tcr2 Therapeutics stock?
TCRR stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Charles Schwab Investment Management Inc., EcoR1 Capital LLC and Parametric Portfolio Associates LLC. Company insiders that have bought Tcr2 Therapeutics stock in the last two years include Morana Jovan-Embiricos and Upnorth Investment Ltd. View Insider Buying and Selling for Tcr2 Therapeutics.
How do I buy shares of Tcr2 Therapeutics?
Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Tcr2 Therapeutics' stock price today?
One share of TCRR stock can currently be purchased for approximately $17.00.
How big of a company is Tcr2 Therapeutics?
Tcr2 Therapeutics has a market capitalization of $407.42 million. The company earns $-24,250,000.00 in net income (profit) each year or ($98.53) on an earnings per share basis. Tcr2 Therapeutics employs 47 workers across the globe.View Additional Information About Tcr2 Therapeutics.
What is Tcr2 Therapeutics' official website?
How can I contact Tcr2 Therapeutics?
Tcr2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]
MarketBeat Community Rating for Tcr2 Therapeutics (NASDAQ TCRR)
MarketBeat's community ratings are surveys of what our community members think about Tcr2 Therapeutics and other stocks. Vote "Outperform" if you believe TCRR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCRR will underperform the S&P 500 over the long term. You may vote once every thirty days.
